Aranzazu Fernandez-Martinez

5PUBLICATIONS
55CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 26, 2026
Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.

Ang Gao, Parth H Khatri, Gui Ma

|Jul 09, 2025
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil

|Mar 06, 2024
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.

Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal

|Jan 19, 2022
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.

Jonathan H Shepherd, Karla Ballman, Mei-Yin C Polley

|Oct 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.

Aranzazu Fernandez-Martinez, Ian E Krop, David W Hillman

Pageof 1

Frequent Collaborators

4 joint publications

Charles M Perou

2 joint publications

Adam D Pfefferle

2 joint publications

Mei-Yin Polley

2 joint publications

Katherine A Hoadley